NCT01552434
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Therapeutic Antibody, Misc Inhibitor
Key Eligibility Criteria:
Gender: All
Age: Child, Adult), Senior)
Location of Metastases:
Additional Notes:
Exclusions:
https://ClinicalTrials.gov/show/NCT01552434